Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy
International Journal of Clinical Oncology, 08/20/2012
Li Y et al. – Low–dose homoharringtonine (HHT) alone has considerable short–term efficacy for high–risk polycythemia vera (PV) and essential thrombocythemia (ET) and may used as a second–line drug for PV/ET treatment in patients who have failed or were intolerant to hydroxycarbamide or interferon–α therapy.



